TNFα inhibition in MRL/lpr mice ameliorates pulmonary but not renal disease

Journal of Autoimmunity

Volumn 19, Issue 4, 2002, Pages 215-222

  Kim, Nahmah ^a   Ussin, LaShon ^a   Cheng, Xin ^b   Murali, Ramachandran ^b   Sullivan, Kathleen E ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Dermatitis; Lupus; MRL lpr; Nephritis; TNF ; Vasculitis

Indexed keywords

DNA ANTIBODY; ETANERCEPT; PEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; KIDNEY DISEASE; LUNG DISEASE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; SPLEEN;

ANIMALS; ANTIBODIES; DNA; FEMALE; KIDNEY DISEASES; LUNG DISEASES; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED MRL LPR; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037005436     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2002.0617     Document Type: Article

References (57)

1. Sobel E.A., Mohan C., Morel L., Schiffenbauer J., Wakeland E.K. Genetic dissection of SLE pathogenesis: adoptive transfer of SLE1 mediates the loss of tolerance by bone marrow derived B cells. J. Immunol. 162:1999;2415-2421.
2. Nemazee D., Guiet C., Buerki K., Marshak-Rothstein A. B lymphocytes from the autoimmune-prone mouse strain MRL/lpr manifest an intrinsic defect in tetraparental MRL/lpr-DBA/2 chimeras. J. Immunol. 147:1991;2536-2539.
3. Perkins D.L., Glaser R.M., Mahon C.A., Michaaelson J., Marshak-Rothstein A. Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J. Immunol. 145:1990;549-555.
4. Yokoyama H., Kreft B., Kelley V.R. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 47:1995;122-130.
5. Kreft B., Yokoyama H., Naito T., Kelley V.R. Dysregulated transforming growth factor-beta in neonatal and adult autoimmune MRL-lpr mice. Journal of Autoimmunity. 9:1996;463-472.
6. Feusi E., Sun L., Sibalic A., Beck-Schimmer B., Oertli B., Wuthrich R. Enahnced hyaluronan synthesis in MRL-Fas(lpr) kideny: role of cytokines. Nephron. 83:1999;66-73.
7. Criscione L.G., Doyle M.K., Glimcher L.H., Kelley V.R., Gravallese E.M. TNFa is expressed early in skin lesions in MRL/lpr mice followed by an increase in IL-10. Arthritis Rheum. 40:1997;S79.
8. Hecht M., Muller M., Lohmann-Matthes M.L., Emmendorffer A. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. Journal of Leukocyte Biology. 57:1995;242-249.
9. Moore K.J., Yeh K., Naito T., Kelley V.R. TNF-alpha enhances colony stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J. Immunol. 157:1996;427-432.
10. Edwards C.K., Zhou T., Zhang J. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-a. J. Immunol. 157:1996;1758-1772.
11. Brennan D.C., Yui M.A., Wuthrich R.P., Kelley V.E. Tumor necrosis factor and IL-1 in New Zealand black/white mice. J. Immunol. 143:1989;3470-3475.
12. Satake F., Watanabe N., Miyasaka N., Kanai Y., Kubota T. Induction of anti-DNA antibodies by immunization with anti-DNA antibodies: mechanism and characterization. Lupus. 9:2000;489-497.
13. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G., Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus. J. Immunol. 158:1997;3009-3016.
14. Segal R., Dayan M., Zinger H., Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus. 10:2001;23-31.
15. Segal R., Dayan M., Zinger H., Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin. Exp. Immunol. 101:1995;66-72.
16. Bertani T., Abbate M., Zoja C. Tumor necrosis factor alpha induces glomerular damage in the rabbit. Am. J. Path. 134:1989;419-430.
17. Carballo E., Gilkeson G.S., Blackshear P.J. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. J. Clin. Invest. 100:1997;986-995.
18. Carballo E., Lai W.S., Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-a production by tristetraprolin. Science. 281:1998;1001-1005.
19. Taylor G.A., Carballo E., Lee D.M. A pathologic role for TNFa in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 4:1996;445-454.
20. Jacob C.O., Lee S.K., Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J. Immunol. 156:1996;3043-3050.
21. Cope A.P., Londei M., Chu N.R. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94:1994;749-760.
22. Jacob C.O., Hwang F., Lewis G.D., Stall A.M. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine. 3:1991;551-561.
23. Gordon C., Wofsy D. Effects of recombinant murine tumor necrosis factor-a on immune function. J. Immunol. 144:1990;1753-1758.
24. Gordon C., Ranges G.E., Greenspan J.S., Wofsy D. Chronic therapy with r ecombinant tumor necrosis factor-a in autoimmune NZB/NZW F1 mice. Clin. Immunol. Immunopathol. 52:1989;421-434.
25. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZ B/W F1 mice. J. Exp. Med. 179:1994;305-310.
26. Kalechman Y., Gafter U., Da J.P., Albeck M., Alarcon-Segovia D., Sredni B. Delay in the onset of system immunomodulator AS 101. J. Immunol. 159:1997;2658-2667.
27. Via C.S., Shustov A., Rus V., Lang T., Nguyen P., Finkelman F.D. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167:2001;6821-6826.
28. Herrerea-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., Avalos-Diaz E. Renal expression of IL-6 and TNF-alpha genes in lupus nephritis. Lupus. 7:1998;154-158.
29. Yokoyama H., Wada T., Ohta S. Glomerular ICAM-1 expression related to circulating TNF-alpha in human glomerulonephritis. Nephron. 76:1997;425-433.
30. Linker-Israeli M., Deans R.J., Wallace D.J., Prehn J., Ozeri-Chen T., Klinenberg J.R. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J. Immunol. 147:1991;117-123.
31. Meijer C., Huysen V., Smeenk R.T.J., Swaak A.J.G. Profiles of cytokines (TNFα and IL-6) and acute phase proteins (CRP and al AG) related to disease course in patients with systemic lupus erythematosus. Lupus. 2:1993;359-365.
32. Studnicka-Benke A., Steiner G., Petera P., Smolen J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Brit. J. Rheum. 35:1996;1067-1074.
33. Klausner J.D., Freedman V.H., Kaplan G. Thalidomide as an anti-TNFα inhibitor: implications for clinical use. Clin. Immunol. Immunopathol. 81:1996;219-223.
34. Atra E., Sato E.I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clinical & Experimental Rheumatology. 11:1993;487-493.
35. Sato E.I., Assis L.S.S., Furtado R. Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus. Arthritis Rheum. 9:1996;1353.
36. Stevens R.J., Andujar C., Edwards C. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. Arthritis Rheum. 39:1996;S253.
37. Werth V.P., Zhang W., Dortzbach K., Sullivan K. Association of a promoter polymorphism of TNFa with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. Journal of Investigative Dermatology. 115:2000;726-730.
38. Danis V.A., Millington M., Hyland V., Lawford R., Huang Q., Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis. Markers. 12:1995;127-133.
39. Wilson A.G., Symons J.A., McDowell T.L., diGiovine F.S., Duff G.W. Effects of a tumor necrosis factor promoter base 167 transition on transcriptional activity. Brit. J. Rheum. 33:1994;89.
40. Sullivan K.E., Wooten C., Schmeckpeper B., Goldman D., Petri M. A promoter polymorphism of tumor necrosis alpha is associated with systemic lupus erythematosus in African Americans. Arthritis Rheum. 40:1997;2207-2211.
41. Alvarado-de la Barrera C., Alcocer-Varela J., Richaud-Patin Y., Alarcon-Segovia D., Llorente L. Differential oncogene and TNFa mRNA expression in bone marrow cells from systemic lupus erythematosus patients. Scand. J. Immunol. 48:1998;551-556.
42. Jacob C.O., Fronek Z., Lewis G.D., Koo M., Hansen J.A., McDevitt H.O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl Acad. Sci. USA. 87:1990;1233-1237.
43. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2000;2383-2390.
44. Weinblatt M.E., Kremer J.M., Bankhurst A.D. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:1999;253-259.
45. Lovell D.J., Giannini E.H., Reiff A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342:2000;763-769.
46. Wakeland E.K., Liu K., Graham R.R., Behrens T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 15:2001;397-408.
47. Takasaki W., Kajino Y., Kajino K., Murali R., Greene M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat. Biotechnol. 15:1997;1266-1270.
48. Deguchi Y., Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin. Exp. Immunol. 85:1991;392-395.
49. Kanauchi H., Furukawa F., Imamura S. Evaluation of ATPase-positive Langerhans' cells in skin lesions of lupus erythematosus and experimentally induced inflammations. Archives of Dermatological Research. 281:1989;327-332.
50. Boswell J.M., Yui M.A., Burt D.W., Kelley V.E. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141:1988;3050-3054.
51. Lemay S., Mao C., Singh A.K. Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int. 50:1996;85-93.
52. Zhou T., Edwards C.K., Yang P., Wang Z., Bluethmann H., Mountz J.D. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156:1996;2661-2665.
53. Ji H., Ohmura K., Mahmood U. Arthritis critically dependent on innate immune system players. Immunity. 16:2002;157-168.
54. Tremblay C., Paradis M., Dore M. Expression of E- and P-selectin in tumor necrosis factor-induced dermatitis in dogs. Veterinary Pathology. 38:2001;261-268.
55. Colletti L.M., Cortis A., Lukacs N., Kunkel S.L., Green M., Strieter R.M. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock. 10:1998;182-191.
56. Schwarting A., Moore K., Wada T., Tesch G., Yoon H.-J., Kelley V.R. IFN-g limits macrophage expansion in MRL-Fas lpr autoimmune interstitial nephritis: a negative regulatory pathway. J. Immunol. 160:1998;4074-4081.
57. Schwarting A., Wada T., Kinoshitia K., Tesch G., Kelley V.R. IFN-g receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Faslpr Mice. J. Immunol. 161:1998;494-503.